suPAR is a Risk Marker for Kidney Disease in Acute Medical Patients

Fri Jun 12 2020

A new study, published in Frontiers in Cell and Developmental Biology by Iversen E. et al., reveals that high suPAR levels at hospital admission independently mark a higher risk for both chronic and acute kidney disease in acute medical patients. The research aimed to link elevated plasma suPAR levels, measured when patients first arrived at the emergency department, with the likelihood of developing kidney disease later on.

Researchers followed over 25,000 acute medical patients for four years to monitor the onset of kidney disease. They found that each doubling of suPAR levels at admission increased the risk of chronic kidney conditions by 57% and acute kidney conditions by 151%.

These findings underscore suPAR’s value in identifying patients at high risk for kidney diseases and all-cause mortality. Utilizing suPAR in risk classification models can pinpoint patients who might greatly benefit from early clinical interventions. By classifying patients based on their kidney disease risk, healthcare providers can more closely monitor and promptly intervene in high-risk cases, potentially slowing the progression of kidney disease and preventing related complications.

Read the article here

1000+

published suPAR studies in leading medical journals

Nature Medicine Logo
Science Journal Logo
JAMA Pediatrics Logo

The suPARnostic® brand consists of four products:

Quick Triage
TurbiLatex
ELISA
POC+

Quick Triage

A Point of Care Solution

TurbiLatex

For Automated Systems

ELISA Assay

Clinical and Research

POC+

Point-of-care finger prick

New Webinar

Webinar

Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording

suPARnostic® by ViroGates